Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Cortical lesion load associates with progression of disability in multiple sclerosis.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Managing fatigue in patients with multiple sclerosis.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells.
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)

Pages